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Allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment
option for high-risk hematological malignancies, and may also be offered to patients with
solid malignancies refractory to conventional therapies. In case of patients’ relapse, refrac-
tory tumor cells may then be targeted by cellular therapy-based combination strategies.
Here, we investigated the potential of small molecule IAP (SMAC mimetic) BV6 in increas-
ing cytokine-induced killer (CIK) cell-mediated cytotoxicity against different tumor tar-
gets. Four-hour pre-incubation with 2.5µMol BV6 moderately enhanced CIK cell-mediated
lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and
TE671). However, BV6 also increased apoptosis of non-malignant cells like peripheral blood
mononuclear cells and most notably had an inhibitory effect on immune cells potentially
limiting their cytotoxic potential. Hence, cytotoxicity increased in a dose-dependent man-
ner when BV6 was removed before CIK cells were added to tumor targets. However,
cytotoxic potential was not further increasable by extending BV6 pre-incubation period of
target cells from 4 to 12 h. Molecular studies revealed that BV6 sensitization of target cells
involved activation of caspases. Here, we provide evidence that SMAC mimetic may sen-
sitize targets cells for CIK cell-induced cell death. However, BV6 also increased apoptosis
of non-malignant cells like CIK cells and peripheral mononuclear cells. These findings may
therefore be important for cell- and small molecule IAP-based combination therapies of
resistant cancers after allogeneic HSCT.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is
an established strategy for treatment of high-risk hematological
malignancies, and is also offered to patients with solid malignan-
cies refractory to conventional therapies (1). But still, due to tumor
cell resistance, the therapeutic success of this approach is limited
by patients’ relapse. Hence, new therapeutic strategies are needed,
which may combine cellular therapies and small molecule drugs
for retargeting of resistant tumor cells. Immune cell-based combi-
nation strategies may not only include chimeric antigen receptor
(CAR) bearing T cells (2, 3), T cell receptor (TCR) transduced T
cells (4, 5), or specific cytotoxic T lymphocyte (CTL) clones (6, 7),
but may also include non-specific immune cell approaches using
cytokine-induced killer (CIK) cells.
CIK cells are activated and expanded in vitro from periph-
eral blood mononuclear cells (PMNCs) by timed addition of
cytokines. Expanded CIK cells represent a heterogeneous popu-
lation of CD3+CD56− T cells and CD3−CD56+ natural killer
(NK) cells. T cells in part share both CD3+ T cell and CD56+
NK cell phenotype (CD3+CD56+ T-NK cells). CIK cells are able
to eradicate a variety of hematological and solid malignancies in a
non-major histocompatibility complex (MHC)-restricted manner
without possessing significant alloreactive potential (8–17). There-
fore, the application of CIK cells has evolved from experimental
observations into early clinical allogeneic HSCT studies. These
trials included transplanted patients who had relapsed from hema-
tological malignancies. Most of these patients showed transient
clinical responses after CIK cell infusions (18–20). Anti-leukemic
activity of CIK cells, without long lasting efficacy, may suggest
limited lifespan of infused CIK cells or resistance mechanisms
developed by target cells.
Inhibitors of apoptosis (IAP) proteins are associated with
chemo-resistance, disease progression, and poor prognosis in dif-
ferent cancers (21, 22). Therefore, IAPs may be interesting for
retargeting tumor cells toward unspecific CIK cell-based killing by
using a combination of CIK cells and small molecule IAP (SMAC
mimetics/IAP antagonists) (23).
The divergent structures of SMAC mimetics originate
from the conserved AVPI tetrapeptide N-terminal sequence of
SMAC/DIABLO (direct inhibitor of apoptosis-binding protein
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with low isoelectric point/direct IAP-binding protein with low pI)
that binds to the BIR domains of IAP proteins with high affinities
to promote cell death and inhibit tumor growth in in vivo models.
In response to apoptotic stimuli, following the death trigger, mito-
chondria may become selectively permeabilized, SMAC along with
pro-apoptotic proteins such as cytochrome c are released from the
intermembrane space of mitochondria into the cytoplasm (24).
SMAC is a dimer and interacts with its four N-terminal amino acid
residues (AVPI) with XIAP to abrogate XIAP-mediated inhibition
of caspases-3 and -9 leading to dissociation of bound caspases
from XIAP (25).
One important contribution of IAP proteins to cell survival
and tumorigenesis is the ability of several IAP proteins to regu-
late alternative nuclear factor (NFκB) signaling. cIAP1 and cIAP2
are involved in degradation of the MAP3 kinase, NFB inducing
kinase (NIK) in the NFκB pathway (23, 26–29), and contribute to
activation of the classical NFκB pathway by tumor necrosis factor
(TNF) stimulation (30–32). Besides preventing the XIAP interac-
tion with caspases, SMAC mimetics induce activation of the NFκB
pathway by binding to cIAP1 and cIAP2 and stimulating the E3
ubiquitin-ligase activity of the cIAP proteins (33).
So far, several small molecules that mimic the IAP binding of
motif of SMAC and pharmacologically inhibit IAP protein func-
tion were designed and described (34). Beside BV6 (23), birina-
pant (TL32711) a biindole-based bivalent SMAC mimetic recently
showed promising synergistic cytotoxicity of several widely used
anti-cancer agents in pre-clinical analyses (35, 36).
This study was performed to assess the role of bivalent SMAC
mimetic BV6 in increasing susceptibility of target cells toward
CIK cell-mediated killing in cell line models. Our findings may be
important for cell-based combination strategies in the treatment
of resistant tumor cells.
MATERIALS AND METHODS
CELL LINES
T cell lymphoma cell line H9, subtype M4 acute myeloid leukemia
cell line THP-1, precursor-B acute lymphoblastic leukemia cell line
Tanoue, Ewing sarcoma cell line RH1, alveolar rhabdomyosarcoma
cell line RH30, and embryonal rhabdomyosarcoma cell line TE671
were obtained and cultured as previously described (13, 17).
CIK CELLS
CIK cells were generated as previously described from PMNCs
of healthy donors in accordance with the institutional review
board approval and after written informed consent (Geschäfts-
Nr.: 298/07) (17). In brief, after 10 days of in vitro stimulation with
interferon (IFN)-γ, anti-CD3 antibody, and interleukin (IL)-2 and
IL-15, CIK cells were harvested and used in experiments.
EUROPIUM RELEASE ASSAY
Europium release assay was used to assess lytic activity of CIK cells
with or without pre-treatment of target cells with SMAC mimetic
BV6. In brief, target cells used (H9, THP-1, Tanoue, RH1, RH30,
TE671, and PMNCs) were labeled with BATDA (DELFIA® BATDA
Labeling Reagent, PerkinElmer, Waltham, MA, USA). Labeled tar-
get cells were pre-incubated with 2.5µMol BV6 for 4 h or remained
without BV6 treatment. To further analyze dosage and timing of
target cell sensitization by BV6, selected hematological and solid
malignancies (THP-1 and RH30) were labeled with BATDA, sensi-
tized with 2.5 and 10µMol BV6 for 4 h and were washed to remove
BV6 before being used in experiments. In addition, more resistant
targets cell lines (RH30 and TE671) were pre-incubated with 2.5
and 10µMol BV6 for 12 h and were washed before being labeled
and introduced to CIK cells in experiments.
Next, these different pre-treated target cells were cultured on
U-bottomed-96-well culture plates (NUNC, Langenselbold, Ger-
many). CIK cells were added at an effector to target cell (E:T)
ratio of 20:1. After another period of 3 h, 20µL of supernatant
was collected out of each well and introduced to 200µL europium
solution (Europium, Perkin Elmer, Turku, Finland). Fluorescence
data were recorded using a time resolved fluorometer (1420-018
Victor, Perkin Elmer, Waltham, MA, USA). The measured signal
correlated with the amount of destroyed cells. Maximum release
of BATDA was obtained by incubating target cells with 4% tri-
ton (Triton X-100, Sigma-Aldrich, Munich, Germany). Target
cells without effector cells were used as negative control (spon-
taneous release). The percentage of specific cytolysis was calcu-
lated as experimental release minus spontaneous release divided
through maximum release minus spontaneous release of target
cells multiplied by 100.
FLOW CYTOMETRY
Malignant and non-malignant target cells THP-1 and PMNCs
were incubated for 4 h with 2.5 and/or 10µMol BV6 followed
by co-incubation with CIK cells at an E:T ratio of 5:1 for 3 h.
BV6 pre-treated target cells and CIK cells alone served as con-
trols. Cell suspensions were then stained using FITC Annexin
V Apoptosis Detection Kit with 7AAD (Bio Legend, San Diego,
CA, USA) according to the manufacturer’s instructions. Anti-
human CD3-PC7, CD25-PE, and CD33-PE (Beckman Coulter,
Krefeld, Germany) as well as forward scatter were used to differ-
entiate between CD33+ THP-1, CD3±CD25+ CD33± CIK cells
and CD3±CD25± PMNCs by flow cytometry (FC500 Beckman
Coulter). Percentages of Annexin V-positive apoptotic and 7AAD-
positive necrotic cells are shown. Cytotoxicity results included
Annexin V-positive and/or 7AAD-positive cells.
IMMUNOFLUORESCENT STAINING AND CONFOCAL MICROSCOPY
Target cells were grown together with CIK cells in chamber slides.
Cells were fixed with 4% paraformaldehyde, permeabilized with
0.2% triton X-100 for 30 min, and intracellularly stained with
caspase-3 phycoerythrin (PE)-labeled for 30 min at room temper-
ature. To distinguish between CIK and RH30 cells, CIK cells were
stained with fluorescein isothiocyanate (FITC)-labeled anti-CD45
antibody for 30 min at room temperature. Images were obtained
using a confocal microscope. Images were computer processed by
Zeiss LSM Image Browser.
WESTERN BLOT ANALYSIS
BV6-mediated killing mechanism was analyzed in co-cultures of
tumor and CIK cells. TE671 (TE) cells that were efficiently killed
by combination therapy and grown in adherent cultures allow-
ing a segregation of effector and target cells by several washing
steps were used for analyses. Analyzed samples included TE and
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CIK cells alone, TE and CIK cells pre-incubated with 2.5µMol
BV6 for 4 h, TE cells co-cultured with CIK cells at an E:T ratio of
20:1 for 3 h, and TE cells pre-incubated with 2.5µMol BV6 for 4 h
followed by co-culture with CIK cells at an E:T ratio of 20:1 for
3 h. Co-cultures of TE and CIK cells were washed for the removal
of CIK cells before TE cells were analyzed by western blot analy-
sis. Western blot analysis was performed as described previously
using the following antibodies: mouse anti-caspase-8 (1:1000;
Alexis Biochemicals, Gruenberg, Germany), rabbit anti-Bid, rabbit
anti-caspase-3, and rabbit anti-caspase-9 (1:1000; Cell Signaling,
Beverly, MA, USA). Mouse anti-β-actin (1:10000; Sigma) was used
as loading control (37). Goat anti-mouse IgG and goat anti-rabbit
IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were used as secondary
antibodies. Enhanced chemiluminescence was used for detection
(Amersham Bioscience, Freiburg, Germany).
INHIBITION OF CASPASE ACTIVATION BY zVAD
BV6 and CIK cell-mediated cytotoxicity mechanism was ana-
lyzed by europium release assay against TE671 cells after 4 h
pre-incubation with 2.5µMol BV6. To analyze whether BV6 and
CIK cell treatment induces apoptosis by caspase activation, 50 mM
zVAD was added. zVAD is a cell-permeant pan caspase inhibitor
that irreversibly binds to the catalytic site of caspase proteases and
inhibits induction of apoptosis by the caspase cascade.
STATISTICAL ANALYSIS
Statistical significance was assessed by two-sided Student’s t-test
using PRISM 6. Results from independent experiments are shown
as mean with standard error of the mean (SEM).
RESULTS
CYTOTOXICITY OF CIK CELLS AGAINST TUMOR CELLS IN THE
PRESENCE OF BV6
Europium release assay was performed to evaluate the effect of
BV6 on CIK cell-mediated killing of tumor targets. Thereafter, CIK
cells were added for 3 h at an E:T ratio of 20:1. Europium release
measurements confirmed CIK cell-mediated target cell killing in
the presence of BV6 (Figure 1). Combination treatment of CIK
cells and BV6 was referred to standard control without BV6 and
resulted in moderately increased lysis of targets cells in the pres-
ence of 2.5µMol BV6 (Figure 1: H9, (A); THP-1, (B); Tanoue, (C);
RH1, (D); RH30, (E); TE671, (F)).
CYTOTOXICITY OF CIK CELLS AGAINST NON-MALIGNANT PMNCs IN
THE PRESENCE OF BV6
To mimic cytotoxic potential of combination therapy of CIK cells
and BV6 against non-malignant cells like PMNCs, the latter were
freshly isolated by Ficoll® density centrifugation, labeled, treated
in part with BV6, and used for analysis in europium release assay.
Combination treatment significantly increased CIK cell-mediated
killing of PMNCs (mean± SEM: w/o BV6, 16.0± 0.4%; 2.5µMol
BV6, 22.0± 0.4%, p< 0.0001, (n= 4); Figure 2A).
This analysis was also performed by flow cytometry as cytol-
ysis of non-malignant cells may limit applicability of combina-
tion therapy. Therefore, PMNCs treated with 2.5µMol BV6 and
untreated PMNCs were incubated with CIK cells at an E:T ratio
of 5:1. For analysis of apoptotic and necrotic cells, cell suspen-
sions were stained with Annexin V FITC and 7AAD, respectively.
PMNCs were identified by forward scatter and CD25-expression
and excluding CD25-expressing larger CIK cells. Compared to
FIGURE 1 | CIK cell-mediated killing of malignant cells in the
presence of BV6. The potential of BV6 to increase CIK cell-mediated
killing of hematological (H9, T cell lymphoma (A); THP-1, subtype M4
acute myeloid leukemia (B); Tanoue, precursor-B acute lymphoblastic
leukemia (C)) and solid tumor targets (RH1, Ewing sarcoma (D); RH30,
alveolar rhabdomyosarcoma (E); TE671, embryonal rhabdomyosarcoma
(F)) was analyzed by europium release assay. Therefore, target cells
were incubated with 2.5µMol BV6 for 4 h or remained untreated.
Thereafter, CIK cells were added for 3 h at an E:T ratio of 20:1. Results
of at least three independent experiments are shown as mean with
standard error of mean (mean±SEM). Treatment with CIK cells alone
served as standard control. Combination treatment of CIK cells and
BV6 resulted in slightly increased lysis of targets cells in the presence
of 2.5µMol BV6.
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FIGURE 2 | CIK cell-mediated killing of non-malignant cells in the
presence of BV6. Cytotoxic potential of CIK cells combined with BV6 was
analyzed against non-malignant cells like peripheral blood mononuclear cells
(PMNCs, E:T ratio 20:1) by europium release assay (A). Analysis of four
independent experiments demonstrated as means with standard error of
mean (mean±SEM) revealed that combination treatment significantly
increased CIK cell-mediated killing of PMNCs. However, cytotoxicity against
non-malignant targets remained relatively low. Accordingly, PMNCs were
treated with 2.5µMol BV6 for 4 h or remained untreated and were incubated
with CIK cells at an E:T ratio of 5:1 for 3 h. For analysis of apoptotic and
necrotic cells, cell suspensions were stained with Annexin V FITC and 7AAD,
respectively. PMNCs were further identified by forward scatter and excluding
CD25-expressing larger CIK cells. One representative example showed that
compared to untreated controls PMNCs were not affected by BV6, but by CIK
cell treatment and furthermore by combination therapy (B). Cytotoxicity data
(Annexin V- and/or 7AAD-positive PMNCs) from three independent
experiments show as mean±SEM indicated that BV6 and CIK cell treatment
in combination was also toxic for normal cells (C).
untreated controls (apoptotic cells, 7.3%; necrotic cells, 1.8%),
PMNCs were not affected by BV6 treatment alone (apoptotic
cells, 6.5%; necrotic cells, 1.8%), but were impaired by CIK cell
treatment (apoptotic cells, 11.4%; necrotic cells, 3.8%) and fur-
thermore by combination therapy (apoptotic cells, 16.8%; necrotic
cells, 3.2%) shown by one representative example (Figure 2B).
Flow cytometry results of independent experiments showed that
combination treatment increased CIK cell cytotoxicity toward
PMNCs, but differences were not significant (mean± SEM of
Annexin V- and/or 7AAD-positive PMNCs: w/o BV6, 12.1± 3.2%;
2.5µMol BV6, 27.5± 7.5%, (n= 3); Figure 2C).
CIK CELL CYTOTOXICITY AGAINST TUMOR CELLS AFTER
PRE-TREATMENT AND REMOVAL OF BV6
To analyze whether target cell sensitization by BV6 was increasable,
selected hematological (THP-1, Figure 3A) and solid malignancies
(RH30, Figure 3B) were pre-treated with increasing concentra-
tions of BV6 for 4 h and were washed before being incubated with
CIK cells in the europium release assay. Sequential use of BV6
and CIK cells such that the SMAC mimetic effect is restricted
to the targets, increased CIK cell-mediated killing of RH30 and
THP-1 cells in a dose-dependent manner (THP-1, mean± SEM:
w/o BV6, 64.7± 3.7%; 2.5µMol BV6, 71.3± 2.7%; 10µMol
BV6, 79.3± 4.7%, n.s. (n= 3), Figure 3A; RH30, w/o BV6,
45.0± 2.1%; 2.5µMol BV6, 52.3± 1.5%, p= 0.0446; 10µMol
BV6, 62.3± 2.8%, p= 0.0080, (n= 3), Figure 3B). Hereby, max-
imum cell lysis was achieved after target cell pre-treatment with
10µMol BV6.
In addition, relatively resistant target cell lines like RH30
(Figure 3C) and TE671 cells (Figure 3D) were incubated with
BV6 for 12 h, washed and introduced to CIK cells in the
europium release assay. Extended pre-incubation period also
resulted in significantly increased CIK cell-mediated killing of
RH30 and TE671 cells, but increase of cytotoxicity was not dose-
dependent and was not enhanced compared to 4 h target cell
pre-incubation period (RH30, w/o BV6, 28.0± 3.1%; 2.5µMol
BV6, 40.5± 2.5%, p= 0.0188; 10µMol BV6, 36.3± 1.5%; (n= 4),
Figure 3C; TE671, w/o BV6, 21.7± 8.5%; 2.5µMol BV6,
55.0± 3.1%, p= 0.0087; 10µMol BV6, 57.0± 5.5%, p= 0.0248;
(n= 3), Figure 3D).
CIK CELL CYTOTOXICITY AGAINST TUMOR CELLS IN THE PRESENCE OF
DOSE ESCALATED BV6
Dose escalating effects of BV6 regarding tumor cell sensitiza-
tion toward CIK cell-mediated killing was also analyzed by flow
cytometry. Therefore, THP-1 cells with BV6 pre-treatment were
incubated with CIK cells at an E:T ratio of 5:1. THP-1 cells
alone and THP-1 cells with BV6 or CIK cell treatment alone
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FIGURE 3 | CIK cell cytotoxicity against tumor cells after
pre-treatment and removal of BV6. Results of at least three independent
experiments performed by europium release assay and shown as means
with standard error of mean (mean±SEM) indicated that removal of BV6
after a target cell pre-incubation period of 4 h increased CIK cell-mediated
killing of hematological and solid malignancies like THP-1 (A) and RH30
cells (B) in a dose-dependent manner. Furthermore, europium release
measurements were performed after extending BV6 sensitization period
from 4 to 12 h to increase CIK cell-mediated cytotoxicity towards more
resistant target cells like RH30 (C) and TE671 cell lines (D). Cytotoxicity
results showed that CIK cell-mediated killing of RH30 and TE671 cell lines
was significantly but dose-independently increased, but there was no
further enhancement compared to four-hour per-incubation of target cells
with BV6.
FIGURE 4 | CIK cell-mediated cytotoxicity after dose escalation of BV6
pre-treatment. Cytotoxic effects of both, increasing doses of BV6 and CIK
cells were analyzed by flow cytometry. One representative example is shown
(A). Hereby, THP-1 cells were treated with 2.5 or 10µMol BV6 for 4 h and
were incubated with CIK cells at an E:T ratio of 5:1 for another 3 h. THP-1 and
CIK cells were differentiated by forward scatter and CD33-expression.
Analysis of apoptotic (Annexin V FITC) and necrotic cells (7AAD) showed that
combination therapy increased cytotoxicity against CD33-expressing larger
THP-1 cells. Cytotoxicity data (Annexin V- and/or 7AAD-positive THP-1 cells)
from three independent experiments shown as mean±SEM demonstrated
that BV6 and CIK cell treatment in combination significantly increased
cytolysis of THP-1 cells (B).
served as controls. Flow cytometric analysis of apoptotic (Annexin
V-positive) and necrotic (7AAD-positive) THP-1 cells (shown by
one represented example, Figure 4A) demonstrated that cyto-
toxic effects of BV6 (THP-1, mean± SEM: w/o BV6, 7.4± 0.6%;
2.5µMol BV6, 15.0± 0.6%; 10µMol BV6, 25.5± 2.8%) and CIK
cells (THP-1, mean± SEM: 20.3± 4.6%) alone were moderate,
but significantly increased in a dose-dependent manner after
combining BV6 and CIK cell treatment (THP-1, mean± SEM:
2.5µMol BV6+CIK cells, 27.2± 2.4%; 10µMol BV6+CIK cells,
42.4± 3.3%, Figure 4B).
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INFLUENCES OF BV6 AND TARGET CELLS ON CIK CELLS
To analyze whether BV6 also influences CIK cells and thereby
their cytotoxic potential, CIK cells were analyzed after four-
hour incubation with 2.5 and 10µMol BV6. Results measured
by flow cytometry showed that CIK cells were affected by BV6
in a dose-dependent manner (w/o BV6, apoptotic cells, 5.4%;
necrotic cells, 1.9%; 2.5µMol BV6, apoptotic cells, 12.0%; necrotic
cells, 1.2%; 10µMol BV6, apoptotic cells, 17.8%; necrotic cells,
3.8%) (Figure 5A). Next we analyzed whether killing of target
cells induced apoptosis in CIK cells. To this end, CIK cells were
co-incubation with alveolar rhabdomyosarcoma cell line RH30.
CIK cells were stained with FITC-labeled anti-CD45 antibody.
Induction of apoptosis was shown by expression of caspase-3
stained with PE and visualized by fluorescence microscope analy-
sis. As a sign of ongoing apoptosis, CIK cells being in contact with
tumor cells and tumor cells both expressed caspase-3 (Figure 5B).
Cytotoxicity of BV6 on CIK cells alone or in the presence of malig-
nant (THP-1) and non-malignant cells (PMNC) was analyzed by
flow cytometry. Cytotoxicity results showed that cytolysis of CIK
cells increased with killing of malignant targets and escalating
doses of BV6 (Figure 5C).
CIK CELL-MEDIATED KILLING OF TUMOR CELLS BY BV6 INVOLVES THE
CASPASE CASCADE
Western blot analysis was used to identify underlying killing mech-
anism of combination therapy (Figure 6A). Compared to TE671
(TE) cells (lane 1), CIK cells (lane 2) showed a high activa-
tion of apoptotic pathway. Four-hour pre-incubation with BV6
had no additional effects on TE (lane 3) and CIK cells (lane
4) alone. CIK cell treatment alone (lane 5) or in combination
with SMAC mimetic BV6 (lane 6) increased TE killing by acti-
vation of the caspase cascade (Figure 6A, in lane 5 and 6 TE
results after removal of CIK cells are shown). This was evident
from the increased cleavage of caspase-8, -3, and -9 into active
cleavage fragments in the presence of BV6 and CIK cells, that
is, caspase-8 into active p43 and p41 fragments, caspase-3 into
active p17 and p12 fragments and caspase-9 into active p37 and
p35 fragments. Moreover, Bid was predominately cleaved into
tBid, the activated form of Bid, upon BV6 and CIK cell treat-
ment (Figure 6A). Addition of zVAD a caspase inhibitor reduced
killing of TE671 cells by 50% (Figure 6B). Collectively, these data
demonstrate that BV6 increases susceptibility of TE671 cells to
CIK cell-mediated cytolysis by triggering caspases activation and
apoptosis.
DISCUSSION
Resistance of tumor cells still remains an unsolved problem in
high-risk cancers after allogeneic HSCT. Tumor cells may even
survive additional cell therapeutic strategies for augmentation
of allogeneic effects post-transplant. Sequential therapy with
apoptosis-sensitizing agents was previously shown for chemother-
apy, radiation,HDAC inhibitors, JAK/STAT inhibitors,proteasome
inhibitors, or tyrosine kinase inhibitors, but not CIK cells (38–
46). Improved therapeutic options may therefore include non-
MHC restricted CIK cell infusions combined with targeted cancer
therapies.
FIGURE 5 | Induction of apoptosis in CIK cells by SMAC mimetic or
killing of target cells. (A)The cytotoxic potential of 2.5 and 10µMol of
the SMAC mimetic BV6 on CIK cells was analyzed by flow cytometry.
One representative example showed that CIK cells were affected by
increasing doses of BV6 indicated by escalating levels of apoptotic
(Annexin V) and necrotic (7AAD) CIK cells (A). After 3 h of co-incubation
with alveolar rhabdomyosarcoma cell line RH30 CIK cells adhered to
tumor cells, which was shown by one representative example using
fluorescence microscope analysis (magnification; 16×). CIK cells were
visualized by surface staining with fluorescein isothiocyanate
(FITC)-labeled anti-CD45 antibody (green fluorescence). Nuclei of all
cells were stained with DAPI (blue fluorescence). As a sign of ongoing
apoptosis, CIK cells being in contact with tumor cells and tumor cells
both showed intracellular expression of caspase-3 stained with
phycoerythrin (PE) (red fluorescence) (B). Cytotoxicity of BV6 on CIK
cells alone and in the presence of non-malignant cells (PMNC) and
malignant (THP-1) cells (E:T ratio, 5:1) was analyzed by flow cytometry.
CIK cells within co-cultures were identified by forward scatter and
CD3-, CD25-, and CD33-expression. Cytotoxicity results (mean±SEM
of Annexin V- and/or 7AAD-positive CIK cells) from three independent
experiments showed that cytolysis of CIK cells increased with
escalating doses of BV6 especially against malignant targets (C).
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FIGURE 6 | BV6 and CIK cells reactivate apoptosis inTE671 cells.
TE671 cells (TE) were treated for 4 h with 2.5µM SMAC mimetic BV6
before BV6 was removed and CIK cells were added for 3 h (lane 6). TE
and CIK cells alone (lanes 1 and 2), and after 4 h pre-incubation with
2.5µM BV6 (lines 3 and 4), as well as TE cells after 3 h treatment with
CIK cells (lane 5) served as controls. CIK cells within samples of lanes 5
and 6 were removed, before western blot analysis was performed.
Caspase activation and Bid cleavage were analyzed. Cleavage
fragments are indicated by arrows. β-Actin served as loading control.
CIK cell treatment without (lane 5) or particularly with SMAC mimetic
BV6 (lane 6) increased TE killing by activation of the caspase cascade.
This was evident from the increased cleavage of caspase-8, -3, and -9
into active cleavage fragments in the presence of BV6 and CIK cells,
that is, caspase-8 into active p43 and p41 fragments, caspase-3 into
active p17 and p12 fragments and caspase-9 into active p37 and p35
fragments. Moreover, Bid was predominately cleaved into tBid, the
activated form of Bid, upon BV6 and CIK cell treatment (A). The
addition of zVAD a pan caspase inhibitor reduced CIK cell-mediated
killing of TE671 cells by 50% demonstrating that BV6 sensitized target
cells towards cytotoxicity of CIK cells by caspase activation (B).
Due to the fact that IAP expression or function is deregulated
in many refractory cancers, several IAP-targeting agents includ-
ing SMAC mimetics are currently being tested in vitro and in vivo
in early clinical trials (21–26, 47–51). It was found that SMAC
mimetics allow sensitization of tumor cells for apoptosis induc-
tion by releasing caspases from the inhibitory interaction with IAP
proteins, particular XIAP (49, 52) and that SMAC mimetics have
complex effects on NFκB and TNF signaling (23, 26, 29–31, 51,
53, 54). But, due to the importance of NFκB in immune cells,
SMAC mimetics might also modulate immune cell functions and
therefore influence cell-based combination therapies, e.g., by mod-
ulating NFκB signaling in immune cells. In this study, we analyzed
the cytotoxic effects of CIK cells against tumor cells in the presence
of the bivalent SMAC mimetic BV6.
Our results showed that BV6 sensitization of hematological
and solid malignancies, i.e., H9, THP-1, Tanoue, RH1, RH30,
and TE671 cell lines toward CIK cell-mediated killing was lim-
ited. To analyze and further increase the impact of BV6 treat-
ment on target cell sensitization, target cells were incubated with
escalating doses of BV6 and incubation period was extended
from 4 to 12 h before BV6 was removed and CIK cells were
added for cytotoxicity analysis. In fact, when used sequen-
tially increased dosage of BV6 correlated with the greater BV6
sensitivity of target cell lines toward CIK cell-mediated killing.
However, cytotoxicity was not further increasable by extending
BV6 incubation period. Monitoring cleavage of caspases by west-
ern blot analysis revealed that CIK cells without or with BV6
increased activation of caspases-3, -8, and -9 and cleavage of
Bid to tBid. The truncated form of Bid (i.e., tBid) links the
extrinsic apoptotic pathway and the intrinsic (mitochondrial)
apoptotic pathway by triggering mitochondrial outer membrane
permeabilization (MOMP).
However, BV6 both sensitized target cells for killing and had an
inhibitory effect on effector cells. For assessment of BV6 effects on
CIK cells, which may limit applicability of combination therapy,
CIK cells were treated with increasing doses of BV6. Remark-
ably, not only BV6 treatment, but also the presence of target cells
alone, induced apoptosis in CIK cells. Accordingly, Nishimura et al.
(55) demonstrated high percentages of early apoptotic cells in
mice transplanted with CIK cells alone, suggesting that CIK cells
per se demonstrated limited life span and increased susceptibil-
ity to apoptosis. Our results confirmed high expression levels of
active caspase-3 fragments as a sign of activated apoptosis path-
ways in CIK cells being in contact with tumor cells. Interestingly,
increased caspase-3-like activity has previously been detected in
non-apoptotic T cells demonstrating that caspase-3-activation
does not necessarily lead to apoptosis (56). Alternatively, CIK cells
may undergo apoptosis during killing of tumor cells. Therefore the
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relevance of caspase activation in CIK cells remains to be explored
in future studies.
Altogether, our results showed that CIK cells were affected by
BV6. However, despite being affected as well by BV6, adding CIK
cells to co-cultures of BV6 and tumor cells significantly increased
cytotoxicity against malignant cells compared to BV6 or CIK cell
treatment alone. This may allow clinical applicability of com-
bination therapy. However, further pre-clinical analyzes will be
mandatory to optimize BV6 dosage and time interval between
BV6 and CIK cell applications. Furthermore, serial CIK cell infu-
sions may be considered in this context. Accordingly, effects of
SMAC mimetic BV6 on conventional immune cells were ana-
lyzed by Muller-Sienerth et al. (57). Considering the role of NFκB
transcription factors in the immune system, they found that BV6-
induced apoptotic and necrotic cell death in monocytes while
T cells, dendritic cells, and macrophages were largely protected
against BV6-induced cell death.
Of note, our results also demonstrated BV6-mediated sensi-
tization of non-malignant cells like PMNCs toward CIK cell-
mediated killing, which may increase risk for graft versus host
disease or graft failure and therefore may complicate the develop-
ment of tumor therapeutic concepts based on CIK cell infusions
combined with BV6 cancer therapies. However, absolute cyto-
toxicity values against PMNCs ranged between 16.0± 0.40% and
22.0± 0.4% while specific lysis of malignant cells reached a max-
imum of 62.3± 2.0% and 76.0± 3.5% without or after addition
of 2.5µMol BV6, respectively. This difference may hint toward
a more selective killing of malignant cells while almost sparing
non-malignant cells. Moreover our clinical data showed that even
in the haploidentical stem cell transplantation setting, alloreac-
tive potential of CIK cells remained low. Here, serial infusions of
1× 108 CD3+CD56− CIK cells/kg recipient body weight gener-
ated from the original haploidentical stem cell donor for treatment
of relapse post-transplant were well tolerated and no signs of acute
graft versus host disease occurred (GvHD) (58).
Moreover, due to the diverse character of CIK cells it remained
unclear, which effector cell population was supported most by the
administration of SMAC mimetic BV6. Hence, more specific cell
therapy approaches such as CAR T cells, TCR-transduced T cells,
or specific T cell clones would have been more applicable in com-
bination with BV6. Further analyses may also address the question,
if the effector cell inhibition refers to BV6 per se, or SMAC mimet-
ics in general. Another IAP, i.e., Birinapant (TL32711) a biva-
lent SMAC mimetic that recently afforded synergistic cytotoxicity
of chemotherapeutic agents and displayed significant antitumor
activity at well-tolerated doses in murine xenograft models could
also be analyzed in context of cell therapy-based combination
strategies (35).
In conclusion, CIK cell-mediated cytotoxicity by target cell pre-
treatment with the IAP BV6 was limited as CIK cells were also
affected by BV6. However, cytotoxic effects were dose- and target
cell-dependent and increased especially when BV6 and CIK cells
were used sequentially compared to BV6 or CIK cell treatment
alone. Altogether, the combination strategy of cellular therapies
and IAP may represent a treatment approach for resistant tumor
targets, which still warrants further investigation in pre-clinical
in vitro and in vivo models.
AUTHOR CONTRIBUTIONS
Eva Rettinger, Andreas Glatthaar, Behnaz Ahangarian Abhari,
Sarah Oelsner, Verena Pfirrmann, Sabine Huenecke, and Peter
Bader acquired, analysed, and helped interpret data. Selim Kuçi,
Hermann Kreyenberg,Andre M. Willasch, Thomas Klingebiel, and
Simone Fulda participated in and contributed to the acquisition
and interpretation of data. All authors reviewed and approved the
final version of the manuscript.
ACKNOWLEDGMENTS
The authors would like to thank the LOEWE Center for Cell
and Gene Therapy Frankfurt/Main funded by Hessian Ministry
of Higher Education, Research and the Arts funding reference
number: III L 4- 518/17.004 (2013) and the Else Kröner-Fresenius-
Stiftung (P75/08//A62/08) for funding of this study.
REFERENCES
1. Rettinger E, Willasch AM, Kreyenberg H, Borkhardt A, Holter W,
Kremens B, et al. Preemptive immunotherapy in childhood acute myeloid
leukemia for patients showing evidence of mixed chimerism after allogeneic
stem cell transplantation. Blood (2011) 118:5681–8. doi:10.1182/blood-2011-
04-348805
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-
modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365:725–33.
doi:10.1056/NEJMoa1103849
3. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 cos-
timulation improves expansion and persistence of chimeric antigen receptor-
modified T cells in lymphoma patients. J Clin Invest (2011) 121:1822–6.
doi:10.1172/JCI46110
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al.
Cancer regression in patients after transfer of genetically engineered lympho-
cytes. Science (2006) 314:126–9. doi:10.1126/science.1129003
5. Kronig H, Hofer K, Conrad H, Guilaume P, Muller J, Schiemann M, et al.
Allorestricted T lymphocytes with a high avidity T-cell receptor towards
NY-ESO-1 have potent anti-tumor activity. Int J Cancer (2009) 125:649–55.
doi:10.1002/ijc.24414
6. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adop-
tive cellular therapy for early cytomegalovirus infection after allogeneic stem-
cell transplantation with virus-specific T-cell lines. Lancet (2003) 362:1375–7.
doi:10.1016/S0140-6736(03)14634-X
7. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-
term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related
lymphoproliferative disease in transplant recipients. Blood (2010) 115:925–35.
doi:10.1182/blood-2009-08-239186
8. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-
induced CD3+CD56+ killer cells. Ann Hematol (1997) 74:51–6. doi:10.1007/
s002770050257
9. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, et al.
Alloreactivity and anti-tumor activity segregate within two distinct subsets of
cytokine-induced killer (CIK) cells: implications for their infusion across major
HLA barriers. Int Immunol (2008) 20:841–8. doi:10.1093/intimm/dxn042
10. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, et al.
Cytokine-induced killer cells are terminally differentiated activated CD8 cyto-
toxic T-EMRA lymphocytes. Exp Hematol (2009) 37(616–628):e612. doi:10.
1016/j.exphem.2009.01.010
11. Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM. Characterization of the
recognition and functional heterogeneity exhibited by cytokine-induced killer
cell subsets against acute myeloid leukaemia target cell. Immunology (2009)
126:423–35. doi:10.1111/j.1365-2567.2008.02910.x
12. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti
A. Cytokine induced killer cells as adoptive immunotherapy strategy to aug-
ment graft versus tumor after hematopoietic cell transplantation. Expert Opin
Biol Ther (2009) 9:831–40. doi:10.1517/14712590903005552
13. Kuci S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, et al. Efficient lysis
of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for
Frontiers in Pediatrics | Pediatric Oncology July 2014 | Volume 2 | Article 75 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rettinger et al. BV6 and CIK cell therapy
adoptive immunotherapy after allogeneic stem cell transplantation. Haemato-
logica (2010) 95:1579–86. doi:10.3324/haematol.2009.019885
14. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside.
J Biomed Biotechnol (2010) 2010:435745. doi:10.1155/2010/435745
15. Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, et al. Dual-
functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires
NK function and retains TCR-mediated specific cytotoxicity. Blood (2011)
118:3301–10. doi:10.1182/blood-2011-02-336321
16. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid
tumors. J Cancer (2011) 2:363–8. doi:10.7150/jca.2.363
17. Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, et al. The
cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells
against leukemia cells. Cytotherapy (2012) 14:91–103. doi:10.3109/14653249.
2011.613931
18. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al.
Repeated infusions of donor-derived cytokine-induced killer cells in patients
relapsing after allogeneic stem cell transplantation: a phase I study. Haematolog-
ica (2007) 92:952–9. doi:10.3324/haematol.11132
19. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, et al.
Adoptive immunotherapy with cytokine-induced killer cells for patients with
relapsed hematologic malignancies after allogeneic hematopoietic cell trans-
plantation. Biol Blood Marrow Transplant (2011) 17:1679–87. doi:10.1016/j.
bbmt.2011.05.012
20. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, et al. The anti-tumour
activity of allogeneic cytokine-induced killer cells in patients who relapse after
allogeneic transplant for haematological malignancies. Bone Marrow Transplant
(2012) 47:957–66. doi:10.1038/bmt.2011.202
21. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies.
Leukemia (2009) 23:467–76. doi:10.1038/leu.2008.329
22. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of
NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 10:561–74.
doi:10.1038/nrc2889
23. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P,
et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activa-
tion, and TNFalpha-dependent apoptosis. Cell (2007) 131:669–81. doi:10.1016/
j.cell.2007.10.030
24. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev (2001)
15:2922–33.
25. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved
XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activ-
ity and apoptosis. Nature (2001) 410:112–6. doi:10.1038/35065125
26. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP
antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007)
131:682–93. doi:10.1016/j.cell.2007.10.037
27. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al.
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiqui-
tination cascade that activates NIK-dependent alternative NF-kappaB signaling.
Nat Immunol (2008) 9:1364–70. doi:10.1038/ni.1678
28. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB acti-
vation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A (2008)
105:3503–8. doi:10.1073/pnas.0707959105
29. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Non-
canonical NF-kappaB activation requires coordinated assembly of a regulatory
complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.
Nat Immunol (2008) 9:1371–8. doi:10.1038/ni.1676
30. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al.
Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc
Natl Acad Sci U S A (2008) 105:11778–83. doi:10.1073/pnas.0711122105
31. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K,
et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha
(TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 283:24295–9.
doi:10.1074/jbc.C800128200
32. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al.
Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-
R1 signaling complex and is required for TNF-mediated gene induction. Mol
Cell (2009) 36:831–44. doi:10.1016/j.molcel.2009.10.013
33. Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, et al.
Antagonists induce a conformational change in cIAP1 that promotes autoubiq-
uitination. Science (2011) 334:376–80. doi:10.1126/science.1207862
34. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer.
Nat Rev Drug Discov (2012) 11:109–24. doi:10.1038/nrd3627
35. Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM,Yu G, et al. Biri-
napant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs,
abrogates TNF-induced NF-kappaB activation, and is active in patient-derived
xenograft models. Mol Cancer Ther (2014) 13:867–79. doi:10.1158/1535-7163.
MCT-13-0798
36. Benetatos CA, Burns JM, Borden EC, Lindner D, Mitsuuchi Y, Mckinlay MA,
et al. The Smac Mimetic Birinapant synergistically induces apoptosis in com-
bination with type I interferons and GM-CSF. AARC Annual Meeting (2013)
73:Abstract 3336. doi:10.1158/1538-7445.AM2013-3336
37. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) sys-
tem mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res (1997)
57:3823–9.
38. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic
Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by
binding XIAP and cIAP1 in situ. J Biol Chem (2002) 277:44236–43. doi:10.1074/
jbc.M207578200
39. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma
cells to conventional chemotherapeutic agents: therapeutic applications. Blood
(2003) 101:2377–80. doi:10.1182/blood-2002-06-1768
40. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and
gastric cancers. Oncologist (2004) 9:282–94. doi:10.1634/theoncologist.9-3-282
41. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer
Lett (2004) 215:129–40. doi:10.1016/j.canlet.2004.07.013
42. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases:
targets for cancer therapy. Nat Rev Cancer (2004) 4:361–70. doi:10.1038/nrc1360
43. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic
effects of HDAC inhibitors. Cancer Lett (2009) 280:125–33. doi:10.1016/j.canlet.
2009.02.042
44. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase
cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner.
Cell Death Differ (2010) 17:1645–54. doi:10.1038/cdd.2010.44
45. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, et al.
NF-kappaB is required for Smac mimetic-mediated sensitization of glioblas-
toma cells for gamma-irradiation-induced apoptosis. Mol Cancer Ther (2011)
10:1867–75. doi:10.1158/1535-7163.MCT-11-0218
46. Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, et al. SMAC mimetic
(JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents
in an IAP-dependent but TNF-alpha-independent manner. Cancer Res (2011)
71:7640–8. doi:10.1158/0008-5472.CAN-10-3947
47. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al.
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-
mimetic-induced apoptosis. Cancer Cell (2007) 12:445–56. doi:10.1016/j.ccr.
2007.08.029
48. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, et al.
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regu-
lates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008)
10:1309–17. doi:10.1038/ncb1789
49. Lacasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-
targeted therapies for cancer. Oncogene (2008) 27:6252–75. doi:10.1038/onc.
2008.302
50. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, Mceachern D, Qiu S, et al. SM-164:
a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by
concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res (2008)
68:9384–93. doi:10.1158/0008-5472.CAN-08-2655
51. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation
pathways. Cell (2008) 133:693–703. doi:10.1016/j.cell.2008.03.036
52. Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs
(2009) 20:646–58. doi:10.1097/CAD.0b013e32832ced78
53. Wang CY,Mayo MW,Korneluk RG,Goeddel DV,Baldwin AS Jr. NF-kappaB anti-
apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress
www.frontiersin.org July 2014 | Volume 2 | Article 75 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rettinger et al. BV6 and CIK cell therapy
caspase-8 activation. Science (1998) 281:1680–3. doi:10.1126/science.281.5383.
1680
54. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small
molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death.
Science (2004) 305:1471–4. doi:10.1126/science.1098231
55. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, et al. In vivo
trafficking and survival of cytokine-induced killer cells resulting in mini-
mal GVHD with retention of antitumor activity. Blood (2008) 112:2563–74.
doi:10.1182/blood-2007-06-092817
56. Wilhelm S, Wagner H, Hacker G. Activation of caspase-3-like enzymes in non-
apoptotic T cells. Eur J Immunol (1998) 28:891–900. doi:10.1002/(SICI)1521-
4141(199803)28:03<891::AID-IMMU891>3.0.CO;2-x
57. Muller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU, Schmuck C,
et al. SMAC mimetic BV6 induces cell death in monocytes and maturation
of monocyte-derived dendritic cells. PLoS One (2011) 6:e21556. doi:10.1371/
journal.pone.0021556
58. Rettinger E, Bonig H, Wehner S, Lucchini G, Willasch A, Jarisch A, et al. Feasi-
bility of IL-15-activated cytokine-induced killer cell infusions after haploiden-
tical stem cell transplantation. Bone Marrow Transplant (2013) 48:1141–3.
doi:10.1038/bmt.2013.19
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 15 April 2014; accepted: 03 July 2014; published online: 18 July 2014.
Citation: Rettinger E, Glatthaar A, Abhari BA, Oelsner S, Pfirrmann V, Huenecke S,
Kuçi S, Kreyenberg H, Willasch AM, Klingebiel T, Fulda S and Bader P (2014) SMAC
mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-
induced killer (CIK) cells: a potential challenge for combination therapy. Front. Pediatr.
2:75. doi: 10.3389/fped.2014.00075
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in
Pediatrics.
Copyright © 2014 Rettinger , Glatthaar, Abhari, Oelsner , Pfirrmann, Huenecke, Kuçi,
Kreyenberg , Willasch, Klingebiel, Fulda and Bader. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Pediatrics | Pediatric Oncology July 2014 | Volume 2 | Article 75 | 10
